Stifel Keeps Inovio Pharma (INO) at 'Buy' Following Q1 Report; Cash Position Expected to Remain Firm on New Grants

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. USO
8. IBM
9. HOOD
10. DFTX

Go back to Stifel Keeps Inovio Pharma (INO) at 'Buy' Following Q1 Report; Cash Position Expected to Remain Firm on New Grants

Inovio Pharmaceuticals Reports 2016 First Quarter Financial Results

May 9, 2016 7:50 AM EDT

PLYMOUTH MEETING, Pa., May 09, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today reported financial results for the quarter ended March 31, 2016.

Total revenue was $8.1 million for the three months ended March 31, 2016, compared to $5.2 million for the same period in 2015. Total operating expenses were $23.6 million compared to $13.5 million.

The net loss attributable to common stockholders for the quarter ended March 31, 2016, was $8.0 million, or $0.11 per share, compared to $10.6 million, or $0.17 per share, for the quarter ended March 31, 2015.

Revenue

... More